The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis

Dizon‐Townson, Donna; Nelson, Lesa; Jang, Hyun‐Jun; Varner, Michael W.; Ward, Kenneth

doi:10.1016/s0002-9378(97)70615-x

Cited by 84 publications

(49 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The benefit-to-risk ratio of using thromboprophylaxis in pregnancies of women with a genetic coagulation disorder and other genetic or acquired risk factors, including severe preeclampsia, needs to be evaluated in large, prospective, randomized, controlled studies. 20 In conclusion, in our case-control study we found no increased frequency of the genetic risk factors for throm-bosis in women who had preeclampsia in their first pregnancy compared with control subjects with an uneventful pregnancy m the hospital Unexpectedly, we found a high frequency of factor V Leiden m the control group…”

Section: Commentmentioning

confidence: 43%

Preeclampsia and genetic risk factors for thrombosis: A case-control study

Groot¹,

Bloemenkamp²,

Duvekot³

et al. 1999

American Journal of Obstetrics and Gynecology

130

View full text Add to dashboard Cite

OBJECTIVE:Recently, it has been proposed that hereditary coagulation abnormalities leading to an increased venous thrombosis risk may play a role in the development of preeclampsia. We tested this hypothesis in women who have had preeclampsia compared with matched control subjects. STUDY DESIGN: We conducted a case-control study of 163 women with preeclampsia during 1991-1996. Control subjects were matched for age and delivery date. Patients and control subjects were tested for the presence of factorV Leiden, prothrombin 20210A allele, protein C, protein S, and antithrombin deficiency. Logistic regression methods were used for data analysis. RESULTS:The prevalence of these genetic risk factors was similar in the patient group (12.9%) and the control group (12.9%; odds ratio, 1.0; 95% confidence interval, 0.5-3.9). Unexpectedly, we found a high prevalence of factor V Leiden in the control group (9.2%). CONCLUSION: We found no differences in the prevalence of genetic risk factors of thrombosis in women with preeclampsia compared with control subjects. (Am J Obstet Gynecol 1999;181:975-80.)

show abstract

Section: Commentmentioning

confidence: 43%

Preeclampsia and genetic risk factors for thrombosis: A case-control study

Groot¹,

Bloemenkamp²,

Duvekot³

et al. 1999

American Journal of Obstetrics and Gynecology

130

View full text Add to dashboard Cite

show abstract

“…The risk of venous thrombosis is increased from 3-to 7-fold in individuals heterozygous for FV Leiden , and 80-fold in homozygotes [19,20]. This thrombotic risk is modified by other genetic or environmental risk factors, for example, oral contraceptive use (combined relative risk increased up to 48-fold) [21], pregnancy [22], protein S deficiency [23], hyperhomocysteinemia [24], and increasing age [18]. Some evidence suggests that the risk of PE is not as great as the risk of DVT in FV Leiden individuals (termed the FV Leiden paradox) [25].…”

Section: Background and Molecular Basis Of Fv Leiden And Activated Prmentioning

confidence: 99%

Factor VLeiden

2015

View full text Add to dashboard Cite

Factor V Leiden (FV Leiden ) is a common hereditary thrombophilia that causes activated protein C (APC) resistance. This review describes many of the most fascinating features of FV Leiden , including background features, mechanisms of hypercoagulability, the founder mutation concept, the "FV Leiden paradox," synergistic interaction with other thrombotic risk factors, the intertwined relationship between FV Leiden and APC resistance testing, and other, uncommon mutations implicated in causing APC resistance. In addition, there are several conditions where laboratory tests for APC resistance and FV Leiden are or can be discrepant, including lupus anticoagulants, anticoagulants such as direct thrombin inhibitors (dabigatran, argatroban, and bivalirudin) and rivaroxaban, as well as pseudohomozygous, pseudo-wildtype, liver transplant, and bone marrow transplant patients. The laboratory test error rate for FV Leiden is also presented.

show abstract

“…Systematic reviews are limited by the underlying published studies, the majority of which are retrospective giving an estimate of the magnitude of the increased risk of pregnancy complications which is not reliable and based on the relative risk instead of the absolute risk. Therefore, the expert panel chose to base their evaluation on the results of cohort studies performed in relatives of patients with a particular thrombophilic defect [24][25][26][27][28][29][30][31][32][33]. The overall absolute risk of VTE or obstetric complications is generally low; therefore, there is no clear indication for performing mass screening for thrombophilia.…”

Section: Testing Asymptomatic Women For Thrombophiliamentioning

confidence: 99%

Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Lussana

Dentali

Abbate

et al. 2009

Thrombosis Research

View full text Add to dashboard Cite

The term thrombophilia describes an increased tendency to develop thrombosis and many laboratory markers with different strengths of association with thrombosis have been identified. The main causes of maternal mortality and morbidity in developed countries is venous thromboembolism (VTE) and obstetric complications. During pregnancy and puerperium the risk for VTE increases due to hemostatic imbalance towards a prothrombotic state, and it is further increased in women carriers of thrombophilia; recent studies have also demonstrated an association between thrombophilia and obstetric complications. These complications are, therefore, considered potentially preventable with the prophylactic administration of anticoagulant drugs, although their efficacy is not proven by data from randomized controlled trials. After a systematic comprehensive literature review and using a rigorous methodology, the expert panel formulated recommendations regarding the usefulness of screening for thrombophilia in pregnancy to identify high-risk women and for the management of antithrombotic prophyalxis. When evidence is lacking, consensus-based recommendations are provided.

show abstract

The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis

Cited by 84 publications

References 12 publications

Preeclampsia and genetic risk factors for thrombosis: A case-control study

Preeclampsia and genetic risk factors for thrombosis: A case-control study

Factor VLeiden

Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Contact Info

Product

Resources

About